ArticleFrontiers in aging neuroscience2026
Muscle quality index combined with plasma metabolomics: enhancing risk stratification for post-stroke dementia.
Article in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Post-stroke dementia is a severe long-term stroke complication with heavy medical burdens, and early risk identification is critical. This study explored the association of muscle quality index (MQI) and plasma metabolomics with dementia among stroke survivors. Methods: This study included 7,047 UK Biobank participants with a history of stroke who were free of dementia at the baseline assessment. MQI was defined as dominant handgrip strength (HGS) divided by corresponding arm fat-free mass. Plasma metabolomics was analyzed via high-throughput nuclear magnetic resonance (NMR). Metabolomics risk scores (MRS-ACD, MRS-AD, and MRS-VaD) were constructed using metabolite features screening with LASSO regression and XGBoost algorithms. Statistical analyses included Cox proportional hazards models, time-dependent receiver operating characteristic (TD-ROC), restricted cubic spline (RCS) regression, interaction analyses, Mendelian randomization (MR), and several sensitivity analyses. Results: Higher MQI was associated with lower risks of all-cause dementia (ACD), Alzheimer's disease (AD) and vascular dementia (VaD) (all Conclusion: Joint assessment of MQI and plasma metabolomics provides suggestive evidence for stratifying post-stroke dementia risk and may assist early risk screening in stroke survivors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.